Schwab Equity Ratings Report
Report generated on 02/09/2016, 06:45 AM
Pernix Therapeutics Holdings Inc
Rank: 1 of 100
Data as of 02/05/2016
11:35 AM ET, 02/05/2016 - US Securities and Exchange Commission
December 31, 2015
Filed on: February 5, 2016
SOLE VOTING POWER:
2 Hours Ago
(Adds share reaction, background to the company)
NEW YORK, Feb 8 (Reuters) - Pernix Therapeutics Holdings Inc, a U.S. specialty pharmaceutical company, is exploring strategic alternatives, including a potential sale, people familiar with the matter said on Monday.
The Morristown, New Jersey-based drugmaker is working with investment bank Perella Weinberg Partners LP, the people said. The process is still in its early stages and may not culminate in a sale, the people added.
The sources asked not to be identified because the deliberations are private. Pernix and Perella Weinberg did not respond to requests for comment.
Pernix, which focuses on underserved therapeutic areas, including the central nervous system, has seen its share price decline by more than 80 percent since 2015.
The drop was largely set off by a debt-fueled acquisition of migraine medication Treximet from GlaxoSmithKline Plc in 2014. Treximet has since achieved lower sales than originally forecast by management.
The stock has also been pummeled by the broader slide in biotech shares, the result of increased political criticism of drug prices and soaring market volatility.
Pernix shares jumped as much as 17 percent on the news of a potential sale and were trading up 5 percent at $2.09 in afternoon trading in New York on Monday, giving the company a market capitalization of around $130 million.
The sale process marks a continuation of a trend towards small life sciences companies being pushed to consider a sale in response to reduced access to debt and equity markets.
Pernix carried nearly $500 million in liabilities as of September 2015, much of it in the form of long-term debt.
A close of $0.34 will result in a subsequent acute advance in the stock price of 50% during the following month.
Look to anything else as a catalyst for stock price movement.
January 30th, 2016 - By Renee Johnson
GTX, Inc. Zacks Investment Research upgraded shares of GTX, Inc. (NASDAQ:GTXI) from a hold rating to a buy rating in a research note released on Tuesday. Zacks Investment Research currently has $0.75 price objective on the pharmaceutical company’s stock.
News and Analysis
Mizuho Boosts ZIOPHARM Oncology Inc. (ZIOP) Price Target to $10.00
Posted by Deane Yates on Jan 28th, 2016
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) had its price objective increased by Mizuho from $6.00 to $10.00 in a research note released on Monday morning, Market Beat reports. They currently have a neutral rating on the biotechnology company’s stock.
Several other equities research analysts have also recently commented on ZIOP. JPMorgan Chase & Co. reissued a neutral rating on shares of ZIOPHARM Oncology in a research note on Thursday, November 5th. Zacks Investment Research raised ZIOPHARM Oncology from a sell rating to a hold rating in a research note on Friday, December 11th. Griffin Securities reissued a buy rating and issued a $21.00 price target on shares of ZIOPHARM Oncology in a research note on Thursday, December 10th. Vetr cut ZIOPHARM Oncology from a strong-buy rating to a buy rating and set an $11.88 price target for the company in a research note on Monday, October 12th. Finally, Wells Fargo reissued a sell rating on shares of ZIOPHARM Oncology in a research note on Friday, January 22nd. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $15.63.
Hillary tweeted about Intrexon and Zika:
She said, "It is thoughtful of the company to dedicate themselves to years of work and mega millions of dollars in expenses to discover a cure for this horrible disease. It will be kind of the corporation to give the product away for pennies on the dollar. Hopefully this will happen before they declare bankruptcy, so that management and stockholders can fully appreciate their enriching the lives of all of the poor people in the world."
Two huge block buys at the close. This is the last trading day of January. If those were institutional investors doing some one month window dressing, then it is a feather in the cap of retail investors. Remember the old stock market saying: “Amateurs open the market, but professionals close it". The stock opened at its low and closed 10% higher at its high. So much for the credibility of the so-called professional investors.